Mucocutaneous Leishmaniasis Clinical Trial
Official title:
Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes
"Phase III clinical trial for mucosal or mucocutaneous leishmaniasis. Equivalence between the standard and alternative schemes with meglumine antimoniate" has begun in October 2008 at the Laboratory of Leishmaniasis Surveillance at Evandro Chagas Clinical Research Institute (IPEC), FIOCRUZ, aiming to compare efficacy and safety of the standard recommended schedule with an alternative regimen of meglumine antimoniate (MA) in the treatment of mucosal or mucocutaneous leishmaniasis (ML or MCL)). It is a study with blind evaluation by the doctors and the responsible for statistical analysis. Patients diagnosed with Ml or MCL, eligible for the trial, are randomly allocated into one of the schemes with meglumine antimoniate and monitored before, during and after it. There is no single regimen applicable to all forms of leishmaniasis around the world. Therapeutic regimens applied to treat people living in other geographic areas result in mixed outcomes. Ideally, the most appropriate regimens should be established for each endemic area, based on its efficacy, toxicity, difficulties of administration and cost. Given the problems and limitations of the use of pentavalent antimonials at 20 mg / kg / day, a less toxic alternative regimen with 5mg/kg/day, continuous up to the cure deserves to be better evaluated. Treatment must lead to the healing of mucosal lesions and prevent late scarring tissues and disabilities development. The indication of high doses of MA is based on the evidence that there could be induction of resistance with use of subdoses. However, clinical studies with extended follow-up in Rio de Janeiro have suggested that regular low MA doses (5mg / kg / day) in a systemic way may constitute an effective scheme, achieving cure rates similar to higher dose, with lower toxicity, ease of implementation and lower cost. Published studies on efficacy and safety of alternative schemes with meglumine antimoniate failed to provide conclusive results, for various methodological biases. The need to compare the effectiveness and safety between treatment schemes with meglumine antimoniate currently recommended in Brazil for the treatment of ML or MCL and an alternative scheme with low dose of antimony is the motive for this study in Rio de Janeiro.
1. Introduction. Pentavalent antimonials are first line drugs for the treatment of
leishmaniasis. WHO and Brazilian Ministry of Health recommend treating patients with
mucosal (ML) or mucocutaneous leishmaniasis (MCL) with doses of 20mg/kg/day,
intramuscularly or intravenously, for a period of three to four weeks. In the Reference
Centre on Leishmaniasis - IPEC - FIOCRUZ, the dose of 5mg/kg/day IM has been effective
and well tolerated in the treatment. ML is treated for 30 continuous or intermittent
days, in series of 10 days interspersed with periods of 10 days without medication, up
to 12 series of treatment (120 medication days), with a lower incidence of adverse
effects and lower treatment dropout rates. The evolution of the lesions is usually
similar to that observed with continuous treatment. In all cases patients should be
monitored with clinical examination, electrocardiogram, blood count, liver function,
renal and pancreatic tests. Some side effects can be observed, although they not
necessarily lead to discontinuation of treatment: arthralgia, myalgia, anorexia,
abdominal pain, rash, fever, headache, edema, and herpes zoster. Electrocardiographic
abnormalities most frequent are heart rhythm and ventricular repolarization
disturbances: flattening or inversion of T wave and corrected QT space widening.
2. Background: Ideally, the most appropriate antimoniate therapeutic regimens should be
established for each endemic area, based on their efficacy and toxicity, without
ignoring the difficulties of administration and cost. The treatment of ML or MCL must
achieve the healing of mucosal lesions and prevention of severe scarring of mucosal
tissues and consequent disabilities. The recognition, recommendation and acceptance of
new regimens should be preceded by demonstration of their superiority to currently
recommended treatments. We aim to compare the effectiveness and safety among treatment
schemes with meglumine antimoniate currently recommended in Brazil for the treatment of
ATL and an alternative scheme with low doses of antimony.
3. Objectives. 3.1. General Objective. To compare the effectiveness and safety of meglumine
antimoniate at a dose of 20 mg/kg/day for 30 days or 5 mg continuous up to 120 days, in
the treatment of patients with ML or MCL.
3.2. Specific Objectives. 1. To compare the frequencies of epithelialization and
reduction of mucosal infiltration (assessed on days 30, 120, 150 from the beginning of
the treatment) between the two groups. 2. To compare the frequencies of good late
therapeutic response (maintenance of epithelialization, with total regression of
infiltration and no re-emergence of a skin lesion) between the two groups, up to two
years. 3. To compare the frequency and severity of adverse clinical, laboratory and
electrocardiogram effects between the two groups, controlling for age above or below 60
years. 4. To compare the time in days until the epithelialization and reduction of
infiltration of the lesions between the two groups, according to the nasal,
oropharyngeal or laryngeal location.
4. Subjects and methods.
4. 1. Study design: Controlled clinical trial with standard and alternative treatment,
randomized, double-blind, phase III.
4.2. Description of interventions: Meglumine antimoniate (Aventis, São Paulo, Brazil) is
stored and ministered under actual conditions employed by the health services in Brazil. A
single lot of medication will be used in all patients. Each patient will be included in one
of two treatment groups with meglumine antimoniate IM: 1) 20mg / kg / day for 30 continuous
days. Patients with remaining active lesions in the day 120 from the beginning of the
treatment will be re-treated with the same regimen. 2) 5mg / kg / day continuous until the
epithelization and resolution of mucosal infiltration, respecting the limit of 120 days of
treatment.
There will be no cross-over between the groups for the purpose of this study. The data from
those patients who require permanent discontinuation of a scheme will be assessed in the
group that were randomized, ie, by intention to treat.
4.3. Sampling plan. 4.3.1 Sample size. The comparison of the effectiveness between the two
schemes will probably reveal superiority of the alternative scheme (continuous low dose) for
the following outcomes: 1) frequency of good initial response (epithelialization and
resolution of mucosal infiltration) on day 150. 2) frequency of good late response
(maintenance of epithelialization and total regression of infiltration) up to 2 years.
We considered the significance level of 5% and 80% power to calculate the sample sizes needed
to compare the groups. Initially, a 76-total of patients will be required (38 patients in
each group) to compare the standard group with the alternative group.
4.4 Allocation strategy (randomization). Eligible individuals who agree to participate (by
signing an informed consent) will be randomly assigned to one of the two treatment groups,
according to order of arrival, until the completion of the groups.
4.5. Eligibility Criteria (see item: Eligibility Criteria). 4.6. Outcomes. 4.6.1
Effectiveness Outcome: Definition: 1. Initial therapeutic response - presence or not of
complete epithelization of all lesions until day 150. 2. Late therapeutic response in mucosal
leishmaniasis: maintenance of epithelialization and total regression of the infiltration up
to 2 years.
4.6.2 Safety Outcomes (adverse events): definition, intensity and relationship to study drug.
Adverse events (AE) are considered as any events, adverse or unexpected, evidenced by the
investigator or reported by the patients, beginning during the use of the drug or within 30
days after stopping it. The investigation of AE will be made by spontaneous recall and
questioned by a physician in a standardized form every 10 days during the medication and in
day 30 after completion of treatment. All EA should be monitored until their disappearance.
The classification of the severity of adverse events (clinical, laboratory and
electrocardiographic) will take place according to "AIDS Table for Grading Severity of Adult
Adverse Experiences, 1992". The causal relationship to study drug (= AE) will be evaluated by
the investigator and classified as follows: a) Definite (Highly Likely); b) Probable; c)
Possible; d) Remote (Probably not); e) Definitely not.
4.7. Medications allowed. There will be no restrictions on the use of symptomatic medications
and for other diseases except those listed in the exclusion criteria.
4.8. Management of adverse effects. The AE will be noted in the appropriate form and shall
contain: a description of the adverse effect, its intensity, relation with the investigated
drug, start date, completion date, duration and conduct taken.
4.9. Masking. We chose to perform the measurements of outcomes of interest (effectiveness)
and adverse events (security) by a physician who is not aware of what is the regimen used by
the patient. It is intended to minimize measurement biases of the different outcomes
according to treatment regimen to which each patient belongs. The results of laboratory tests
are provided by the clinical pathology laboratory without information about the treatment
group. The manager of the database will preserve the secrecy of this information by coding
the groups for analysis for the epidemiologist (s).
4.10. Criteria for definitive discontinuation of study treatment: a) Interruption driven by
clinical, laboratory or electrocardiographic AE Grade 4; b) Interruption exceeding 10 days
attributed to clinical, laboratory or electrocardiographic adverse event Grade <3; c)
Spontaneous cessation of the use of prescribed medication beyond five consecutive doses, due
to fault of the administration (noncompliance).
4.11. Criteria for study withdrawal: a) definitive interruption of treatment; b) pregnancy;
c) introduction of immunosuppressive or potentially toxic drugs; d) intercurrent disease,
unrelated to study drug, but with manifestations equivalent or superior to clinical grade 3
AE; e) poor initial or late therapeutic response; f) patient abandonment to continue the
study.
4.12. Procedures for confidentiality break. The randomization codes used for allocation of
numbering and allocation of patients may be revealed in cases of necessity of the study.
4.13. Monitoring the study. The parameters (outcomes) of effectiveness and safety will be
monitored according to the timetable for implementation. The principal investigator and
coordinators will supervise the field work, controlling for quality deviation and this
Protocol. Important items to be monitored: adhesion to the Protocol (follow-up losses will be
minimized through active search), appropriate records of outcomes and adverse events;
adequacy of stored products; quality of procedures for laboratory tests; minimization of
missing data; periodic transmission of data for data entry. Written reports of field will be
retained for consideration by the committees. Serious adverse events will be reported to the
Ethical Committee and perhaps decision to interrupt the test will be made. External
Committee: a committee of outside monitoring of the trial shall be constituted , consisting
of three members, experts in the treatment of leishmaniasis and execution of clinical trials.
The committee will carry out audits of documentation and activities relevant to the clinical
trial, controlling for possible protocol breaks.
4.14 Control of storage of medications. The ampoules required for complete treatment of the
whole sample will be stored in IPEC Pharmacy. A trained professional team will include the
patients, in day 1 consultation, following the randomization list.
4.15. Data Analysis Plan. Data analysis will be carried out following the principle of
intention to treat. The data from those patients who require permanent discontinuation of a
scheme will be analyzed according to the group for what they had been allocated initially,
not being re-assigned to another group to resumption of treatment (no cross-over between the
groups for the purposes of this study). We will describe the simple frequencies of
categorical variables and measures of central tendency and dispersion of continuous
quantitative variables for each antimony scheme. The proportion of dichotomous outcome of
presence or absence of good early and late therapeutic response with the alternative regimen
will be compared to the standard one through chi-square test, and the days until the extent
of epithelialization and reduction of infiltration of lesions by nasal, oropharyngeal or
laryngeal location will be studied through survival time analysis between the two groups
(log-rank statistic). If necessary, nonparametric tests will be used. Effectiveness and
safety will be also evaluated through relative risk (RR), absolute risk reduction (ARR) and
relative risk reduction (RRR).
5. Ethical considerations. 6.1 Risks and benefits. The main potential benefit of this test is
the possibility of subsidizing the use of lower doses of antimony, potentially less toxic and
less costly. The risks consist of general adverse events, which will be thoroughly
scrutinized and treated. This project was submitted to the Ethics in Research Committee
(CEP/IPEC) and National Ethics in Research Council (CONEP). All patients sign an informed
consent approved by CEP/IPEC. This project follows the recommendations of the National Health
Council.
5.2. Informed consent. In plain language and explaining the objectives, risks, benefits and
identifying those responsible for research.
6. Expected Results. We hope the different schemes are equivalent in effectiveness, and with
diverse toxicities.
7. Financial support. This project is supported in part with funds approved by MCT/CNPq /
MS-SCTIE-DECIT 25/2006.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01050907 -
Miltefosine to Treat Mucocutaneous Leishmaniasis
|
Phase 2 | |
| Recruiting |
NCT04799236 -
Treatment of Mucosal Bolivian Leishmaniasis
|
Phase 3 |